Capricor治疗 CAPR 深 沪
等待开盘 12-18 09:30:00 美东时间
26.15
+0.130
+0.50%
华盛通- 最 高26.948
- 今 开25.84
- 成交量 140.27万股
- 最 低 25.60
- 昨 收 26.02
- 总市值 11.96亿
- 52周最高 40.37
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.30
- 委 比 -66.67%
- 总股本 4571.85万
- 历史最高 171.50
- 量 比 0.85
- 振 幅 5.18%
- 历史最低 0.88
- 每 手 1
- 风险率 4.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
https://www.hhs.gov/press-room/secretary-kennedy-adds-duchenne-muscular-dystrophy-metachromatic-leukodystrophy-to-newborn-screenings.html#:~:text=WASHINGTON%E2%80%94DECEMBER%2016%2C%202025%20%E2%80%94,scientific%20review
12-17 00:34
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
B. Riley Securities Reiterates Buy on Capricor Therapeutics, Raises Price Target to $50
B. Riley Securities analyst Madison El-Saadi reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $21 to $50.
12-16 00:48
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
What Does the Market Think About Capricor Therapeutics Inc?
Capricor Therapeutics Inc's (NYSE:CAPR) short interest as a percent of float ha...
12-11 01:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
美股周涨跌榜 | Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购
Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购；UiPath本周上涨34.7%，财报表现强劲>>
12-06 10:17
Capricor Therapeutics prices $150M stock offering
Capricor Therapeutics (CAPR) shares popped over 4% premarket on Friday after the biotechnology company priced an offering to raise $150M. The offering includes 6M shares of common stock issued at a pu...
12-05 19:33
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Analysts’ Top Healthcare Picks: Capricor Therapeutics (CAPR), Insmed (INSM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
12-04 21:50
